UK – MHRA outlines two-year delivery plan with ‘patient first’ focus

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has revealed its new delivery plan, outlining its two-year strategy after departing from the European regulatory system.

The delivery plan, spanning 2021-2023, is aiming to ‘put patients first’ after the Independent Medicines and Medical Devices Safety review revealed a ‘failure to listen to and respond to patients’.

The regulator is also planning to address the challenge of strengthening international regulatory relationships now that the UK is no longer a part of the EU.

The MHRA plans to do this by evolving its regulatory framework with the goal of keeping up with life sciences developments including novel personalised medicines and software and artificial intelligence.

Although the MHRA usually publishes a corporate plan every five years, the regulatory body said that it intends to deliver the ‘more focused’ plan within a shorter time frame…